Page 112 - 《中国药房》2023年8期
P. 112

timolol in the treatment of patients with open angle glau‐  tive  study  of  three  prostaglandin  analogues  in  the  treat‐
               coma or ocular hypertension[J]. Br J Ophthalmol,2001,85  ment  of  newly  diagnosed  cases  of  ocular  hypertension,
              (8):983-990.                                         open-angle  and  normal  tension  glaucoma[J].  Clin  Exp
          [ 6 ]  DUBINER H,COOKE D,DIRKS M,et al. Efficacy and     Ophthalmol,2010,38(7):678-682.
               safety of bimatoprost in patients with elevated intraocular   [19]  KONSTAS A G,HOLLÓ G,IRKEC M,et al. Diurnal IOP
               pressure:a  30-day  comparison  with  latanoprost[J].  Surv   control with bimatoprost versus latanoprost in exfoliative
               Ophthalmol,2001,45(Suppl 4):S353-S360.              glaucoma:a  crossover,observer-masked,three-centre
          [ 7 ]  GANDOLFI S,SIMMONS S T,STURM R,et al. Three-      study[J]. Br J Ophthalmol,2007,91(6):757-760.
               month  comparison  of  bimatoprost  and  latanoprost  in        [20]  KOZ O G,OZSOY A,YARANGUMELI A,et al. Com‐
               patients  with  glaucoma  and  ocular  hypertension[J].  Adv   parison of the effects of travoprost,latanoprost and bima‐
               Ther,2001,18(3):110-121.                            toprost  on  ocular  circulation:a  6-month  clinical  trial[J].
          [ 8 ]  WALTERS T R,DUBINER H B,CARPENTER S P,et al.      Acta Ophthalmol Scand,2007,85(8):838-843.
               24-Hour IOP control with once-daily bimatoprost,timolol   [21]  MISHRA D,SINHA B P,KUMAR M S. Comparing the
               gel-forming solution,or latanoprost:a 1-month,randomi-  efficacy  of  latanoprost(0.005%),bimatoprost(0.03%),
               zed,comparative clinical trial[J]. Surv Ophthalmol,2004,  travoprost(0.004%),and timolol(0.5%)in the treatment
               49(Suppl 1):S26-S35.                                of primary open angle glaucoma[J]. Korean J Ophthalmol,
          [ 9 ]  金晓红,钱韶红,孙兴怀 . 0.03% 贝美前列素滴眼液与                     2014,28(5):399-407.
               0.005%拉坦前列素滴眼液的降眼压效果和安全性比较                     [22]  ORZALESI  N,ROSSETTI  L,BOTTOLI A,et  al.  Com‐
               [J]. 中国实用眼科杂志,2005(7):712-714.                      parison of the effects of latanoprost,travoprost,and bima‐
          [10]  中华医学会眼科学分会青光眼学组,中国医师协会眼科                           toprost  on  circadian  intraocular  pressure  in  patients  with
               医师分会青光眼学组 . 中国青光眼指南:2020 年[J]. 中                    glaucoma  or  ocular  hypertension[J].  Ophthalmology,
               华眼科杂志,2020,56(8):573-586.                           2006,113(2):239-246.
          [11]  APTEL F,CUCHERAT M,DENIS P. Efficacy and tolera-  [23]  PARRISH R K,PALMBERG P,SHEU W P,et al. A com‐
               bility  of  prostaglandin  analogs:a  meta-analysis  of  ran-  parison  of  latanoprost,bimatoprost,and  travoprost  in
               domized controlled clinical trials[J]. J Glaucoma,2008,17  patients  with  elevated  intraocular  pressure:a  12-week,
              (8):667-673.                                         randomized,masked-evaluator multicenter study[J]. Am J
          [12]  HIGGINS  J.  Cochrane  handbook  for  systematic  reviews   Ophthalmol,2003,135(5):688-703.
               of interventions. Version 5.1.0. [EB/OL](2011-03)[2022-  [24]  STALMANS  I,ODDONE  F,CORDEIRO  M  F,et  al.
               08-20]. https://www.cochrane-handbook.org.          Comparison of preservative-free latanoprost and preservative-
          [13]  EGGER  M,DAVEY  SMITH  G,SCHNEIDER  M,et  al.      free bimatoprost in a multicenter,randomized,investigator-
               Bias in meta-analysis detected by a simple,graphical test  masked cross-over clinical trial,the SPORT trial[J]. Albre‐
               [J]. BMJ,1997,315(7109):629-634.                    cht Von Graefes Arch Fur Klinische Und Exp Ophthalmol,
          [14]  Safety and efficacy of bimatoprost compared with latano‐  2016,254(6):1151-1158.
               prost  in  patients  with  glaucoma  or  ocular  hypertension   [25]  WHITSON J T,TRATTLER W B,MATOSSIAN C,et al.
               [EB/OL](2007-10-10)[2022-08-20]. https://clinicaltrials.  Ocular  surface  tolerability  of  prostaglandin  analogs  in
               gov/show/NCT00541242.                               patients with glaucoma or ocular hypertension[J]. J Ocul
          [15]  ARCIERI E S,SANTANA A,ROCHA F N,et al. Blood-      Pharmacol Ther,2010,26(3):287-292.
               aqueous barrier changes after the use of prostaglandin ana‐  [26]  WU J H,WANG T H,HUANG J Y,et al. Ocular surface
               logues  in  patients  with  pseudophakia  and  aphakia:a  6-  disease in glaucoma patients randomized to benzalkonium
               month  randomized  trial[J].  Arch  Ophthalmol,2005,123  chloride-containing  latanoprost  and  preservative-free  bi‐
              (2):186-192.                                         matoprost[J].  J  Ocul  Pharmacol  Ther,2021,37(10):
          [16]  BIRT C M,BUYS Y M,AHMED I I,et al. Prostaglandin   556-564.
               efficacy  and  safety  study  undertaken  by  race:the   [27]  黄海荔,孙兴怀,肖明. 三种前列腺素类滴眼液治疗原发
               PRESSURE study[J]. J Glaucoma,2010,19(7):460-467.   性开角型青光眼的降眼压效果比较[J]. 中华眼科杂志,
          [17]  CELLINI  M,CARAMAZZA  R,BONSANTO  D,et  al.        2011,47(2):109-113.
               Prostaglandin analogs and blood-aqueous barrier integrity:  [28]  孔祥梅,孙兴怀,孟樊荣,等. 三种前列腺素类药物降眼
               a  flare  cell  meter  study[J].  Ophthalmologica,2004,218  压效果比较[J]. 眼视光学杂志,2006,8(4):228-230.
              (5):312-317.                                    [29]  汪梦园,袁军,张慧芝. 四种前列腺素类药物的降眼压疗
          [18]  FARIDI U A,SALEH T A,EWINGS P,et al. Compara‐      效和耐受性对比研究[J]. 眼科新进展,2019,39(10):


          · 998 ·    China Pharmacy  2023 Vol. 34  No. 8                               中国药房  2023年第34卷第8期
   107   108   109   110   111   112   113   114   115   116   117